Search

A recent study conducted at the University of Illinois explored the potential of repurposing the anti-inflammatory drug sulfasalazine for the treatment of adrenocortical carcinomas (ACCs). The research focused on the SLC7A11/xCT pathway and its association with ACC survival, indicating that sulfasalazine could target ACC cells by inducing ferroptosis. In vitro studies showed promising results, suggesting that sulfasalazine downregulates SLC7A11, targets specific pathways, and induces cell death in ACCs, warranting further translational studies to assess its therapeutic potential. [Extracted from the article]

Researchers at GITAM University in Andhra Pradesh, India, have conducted a study on the use of sulfasalazine to induce ferroptosis in oral and breast cancer stem cells. The study found that sulfasalazine downregulated key markers in cancer stem cells, inducing oxidative stress and triggering ferroptosis. This research sheds light on potential new therapeutic approaches for combating drug resistance, cancer recurrence, and relapse in breast and oral cancers. The study was supported by various research institutions in India and the Philippines. [Extracted from the article]

A recent study conducted by investigators from Henan University in Luoyang, People's Republic of China, focused on developing a new treatment approach for Inflammatory Bowel Disease (IBD). The study introduced biocompatible infinite coordination polymers of drugs (Ce-SASP-RS ICPs) composed of Ce ions, sulfasalazine, and resistant starch to address the complex interrelations among IBD pathogenesis factors. The Ce-SASP-RS ICPs were found to restore intestinal metabolic microenvironment by modulating redox balance, attenuating inflammation, and modifying gut microbiota, offering a promising synergistic intervention approach for effectively treating IBD. This research was supported by various funding sources and published in the Journal of Nanobiotechnology. [Extracted from the article]

A study conducted in Uttar Pradesh, India, focused on developing a novel system for treating ulcerative colitis using hybrid nanoparticles-in-microparticles loaded with mesalamine. The research aimed to enhance colon-targeting by combining time-dependent nanoparticles with pH-dependent microparticles. The findings showed that the hybrid nanoparticles-in-microparticles improved drug delivery to the colonic region, prevented burst release, and effectively treated colitis in comparison to other carriers. This research provides a potential alternative for treating inflammatory bowel disease and colorectal cancer. [Extracted from the article]

The article discusses a clinical trial, NCT06668181, conducted by UCB Pharma to evaluate the pharmacokinetics and safety of Bimekizumab in pediatric participants with active juvenile idiopathic arthritis subtypes. The study aims to assess plasma Bimekizumab concentrations following subcutaneous administration and includes outcome measures such as incidence of adverse events, vital signs, biochemistry parameters, and growth assessments. The trial is interventional, in phase 3, and involves the administration of Bimekizumab to study participants aged 2 to less than 18 years with specific arthritis subtypes. [Extracted from the article]

A recent report from Emcure Pharmaceuticals Ltd. in Maharashtra, India, discusses the synthesis, isolation, and characterization of nine pharmacopeial impurities related to the active pharmaceutical ingredient Olsalazine Sodium, which is used to treat ulcerative colitis. The research aims to quantify these impurities to meet quality standards set by the International Council for Harmonisation. This study provides valuable insights into the process-related impurities of Olsalazine Sodium, contributing to the field of Drugs and Therapies - Gastrointestinal Agents. [Extracted from the article]

A study conducted by researchers from Beihua University in Jilin, China, focused on the role of necroptosis in overcoming cisplatin resistance in ovarian cancer cells. The study found that sulfasalazine treatment induced necroptosis in cisplatin-resistant cells, suggesting a potential therapeutic target for overcoming resistance. The research was supported by The Department of Science and Technology of Jilin Province and has been peer-reviewed. For more information, readers can refer to the article "Zinc Finger Domain of P62/sqstm1 Is Involved In the Necroptosis of Human Cisplatin-resistant Ovarian Cancer Cells Treated With Sulfasalazine" published in Oncology Letters. [Extracted from the article]

A patent application has been filed for the use of (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of rheumatoid arthritis. Rheumatoid arthritis is a chronic inflammatory disease that affects the joints and can lead to pain, swelling, and loss of function. Current treatments for rheumatoid arthritis include disease-modifying antirheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), and corticosteroids. The new treatment aims to provide an effective and potentially safer alternative for managing the symptoms of rheumatoid arthritis. [Extracted from the article]

A recent report from researchers at the University Health Network in Toronto, Canada, compares the retention rates and effectiveness of different treatment strategies for rheumatoid arthritis (RA). The study focused on two commonly used combinations of drugs: triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine, and double therapy with methotrexate and leflunomide. The researchers found that patients on triple therapy remained on treatment longer than those on double therapy, and disease activity was lower in the triple therapy group. However, the difference in retention rates between the two groups was not statistically significant. This research provides valuable insights into the treatment options for RA. [Extracted from the article]

A recent study conducted by Butler University in Indianapolis, Indiana, examined the effect of gastric conditions on the release of mesalamine, a drug used in therapy for gastrointestinal conditions. The study found that the release of the drug was influenced by the presence of food in the stomach. Specifically, the study observed that certain formulations of mesalamine had higher drug release in the presence of food, leading to greater systemic absorption. These findings suggest that in vitro dissolution studies simulating gastric conditions can help predict the impact of food on drug release from modified release mesalamine formulations. [Extracted from the article]

A recent study conducted by the Illinois Institute of Technology explores the impact of gut bacteria on the pharmacokinetics of two oral drugs, tacrolimus and sulfasalazine. The researchers found that the presence of certain bacteria can influence the expression of intestinal drug transporters and enzymes, leading to variations in drug bioavailability. Specifically, the study revealed that bacterial modulation reduces the peak blood concentration of tacrolimus but increases the peak plasma concentration of sulfasalazine. These findings suggest that considering the influence of gut bacteria on drug metabolism could improve pharmacokinetic models and address the challenge of variable oral drug bioavailability. [Extracted from the article]

A recent study conducted by the Department of Physics focused on the theoretical analysis of the anti-inflammatory drug Balsalazide. The researchers used quantum computational calculations and various analytical techniques to examine the molecular structure, electronic properties, and charge distribution of the drug. They also conducted molecular docking studies to investigate how Balsalazide interacts with proteins. The research concluded that Balsalazide exhibits drug-like properties and has potential therapeutic applications. For more information, readers can refer to the original article published in Chemical Physics Impact. [Extracted from the article]

The article discusses a clinical trial focused on juvenile idiopathic arthritis (JIA), the most common chronic rheumatic disease in children. The trial aims to analyze peripheral blood lymphocytes in JIA patients to understand disease subtypes and therapy. It explores different subtypes of JIA, the role of immune system cells in JIA, and available treatments such as NSAIDs, DMARDs, and biologic agents. The trial also examines the potential risk of infections associated with these treatments. It highlights that children with JIA may have a higher risk of infection due to their condition and treatments used, but more research is needed on immune cell alterations related to infection control. [Extracted from the article]

A recent study published in the Research Journal of Pharmacy and Technology highlights the design of colon-specific nanoparticles for the delivery of sulfasalazine, a first-line treatment for Inflammatory Bowel Syndrome. Conventional formulations have poor targeting properties for the colon, so the study aimed to formulate and evaluate polymeric nanoparticles loaded with sulfasalazine to improve therapeutic outcomes. The nanoparticles were prepared using a pH-dependent polymer and evaluated for various properties. The optimized formulation showed satisfactory release and may be suitable for colon targeting of sulfasalazine with improved therapeutic effects. [Extracted from the article]

A study conducted at Djillali Liabes University has explored the use of beeswax-based microparticles for the targeted delivery of mesalamine, a drug used in the treatment of gastrointestinal conditions. The researchers prepared beeswax microparticles and then developed bi-layered microspheres with an enteric coating layer. The formulations were characterized using various techniques, and the drug release was evaluated in simulated gastric, small bowel, and colon liquids. The study concluded by discussing the release mechanism using the Korsmeyer-Peppas model. This research provides insights into the potential of beeswax-based microparticles for colon-specific drug delivery. [Extracted from the article]

A recent study conducted by researchers at Kermanshah University of Medical Sciences in Iran has developed a new drug delivery system for Mesalamine, a commonly used treatment for inflammatory bowel diseases. The system utilizes nanofibers made from a combination of psyllium mucilage and poly(vinyl alcohol) to enhance acid resistance and promote prebiotic activity. The nanofibers demonstrated uniformity, smoothness, and adhesion to the mucosal surface. This multi-effect drug delivery system aims to increase the retention of Mesalamine in the intestine and colon. [Extracted from the article]

A recent report from the University of Nottingham in the United Kingdom discusses the development and validation of a prognostic model for monitoring the toxicity of sulfasalazine, a medication used to treat inflammatory conditions. The study aimed to determine the risk of blood, liver, or kidney toxicity during long-term sulfasalazine treatment. The researchers used data from a retrospective cohort study and developed a risk equation using Cox regression analysis. The model utilizes readily available data and can be used to risk-stratify blood-test monitoring for patients on sulfasalazine treatment. [Extracted from the article]

A recent study conducted by researchers at Islamic Azad University in Yazd, Iran, explored the interaction between sulfasalazine (SSZ) and poly (lactic acid) (PLA) using density functional theory (DFT) and time-dependent density functional theory (TDDFT) methods. The study found that the hydrogen double bond interaction between SSZ and PLA was stronger in state I compared to states II and III. The presence of SSZ also caused a modification in the structure of PLA, as evidenced by both experimental and theoretical Infrared (IR) spectra. The findings suggest that SSZ may enhance the solubility and dipole moment of PLA. [Extracted from the article]

A recent report from researchers at the Universite du Quebec a Montreal provides new insights into mesalamine therapy, a commonly used anti-inflammatory agent for treating Ulcerative Colitis. The study investigates the enzymatic processes involved in the oxidation of mesalamine and its side effects. The researchers found that oxidases, such as ceruloplasmin, peroxidase, and hemoglobin, can recognize mesalamine as a substrate and trigger its oxidation. The study also compared the susceptibility of mesalamine to oxidation with other drugs, such as acetaminophen and salicylic acid. The findings contribute to a better understanding of mesalamine therapy and its potential side effects. [Extracted from the article]

Researchers at Islamic Azad University in Tehran, Iran have developed a new nanocomposite material for drug delivery. The material, made from sodium alginate-zein and modified metal-organic framework, shows promise in improving the bioavailability of sulfasalazine, an antiinfective drug. The researchers characterized the nanocomposite using various techniques and found that it exhibited higher antibacterial activity against gram-positive bacteria compared to sulfasalazine alone. This research provides insight into the development of polymer-modified metal-organic framework-based drug delivery platforms and antibacterial agents. [Extracted from the article]

A recent study conducted by researchers at KLE College of Pharmacy focused on the design, characterization, and stability of mesalamine-loaded solid lipid nanoparticles (MES-SLNs). Solid lipid nanoparticles are used as a carrier system for lipophilic medications to enhance their bioavailability. The researchers used glycerylmonostearate as a lipid, Tween 80 as a surfactant, and cremophor as a solubilizing agent in their formulation. They characterized the formulations using various techniques and found that MES-SLNs were stable at -20°C and 40°C. This study provides valuable insights into the development of nanoparticle-based drug delivery systems. [Extracted from the article]

Keywords: 5-aminosalicylates; Amides; Antiinfectives; Cancer; Carcinomas; Drugs and Therapies; Gastroenterology; Gastrointestinal Agents; Health and Medicine; Oncology; Pharmaceuticals; Radiotherapy; Sulfasalazine; Sulfasalazine Therapy; Sulfonamides EN 5-aminosalicylates Amides Antiinfectives Cancer Carcinomas Drugs and Therapies Gastroenterology Gastrointestinal Agents Health and Medicine Oncology Pharmaceuticals Radiotherapy Sulfasalazine Sulfasalazine Therapy Sulfonamides 1165 1165 1 11/06/23 20231109 NES 231109 2023 NOV 6 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A new study on carcinomas is now available. Sulfasalazine was found to be a cost-effective and safe method for reducing the incidence of radiation-induced acute GI toxicities in cervical carcinoma patients undergoing radiotherapy.". [Extracted from the article]

Acute Hepatitis, Amides, Antiinfectives, Blood Cells, Digestive System Diseases and Conditions, Drugs and Therapies, Eosinophilia, Eosinophils, Gastroenterology, Gastrointestinal Agents, Granulocytes, Health and Medicine, Hematologic Diseases and Conditions, Hemic and Immune Systems, Hepatitis, Immunology, Infectious Diseases and Conditions, Leukocyte Diseases and Conditions, Leukocyte Disorders, Liver Diseases and Conditions, Pharmaceuticals, Sulfasalazine, Sulfasalazine Therapy, Sulfonamides, 5-aminosalicylates Keywords: 5-aminosalicylates; Acute Hepatitis; Amides; Antiinfectives; Blood Cells; Digestive System Diseases and Conditions; Drugs and Therapies; Eosinophilia; Eosinophils; Gastroenterology; Gastrointestinal Agents; Granulocytes; Health and Medicine; Hematologic Diseases and Conditions; Hemic and Immune Systems; Hepatitis; Immunology; Infectious Diseases and Conditions; Leukocyte Diseases and Conditions; Leukocyte Disorders; Liver Diseases and Conditions; Pharmaceuticals; Sulfasalazine; Sulfasalazine Therapy; Sulfonamides EN 5-aminosalicylates Acute Hepatitis Amides Antiinfectives Blood Cells Digestive System Diseases and Conditions Drugs and Therapies Eosinophilia Eosinophils Gastroenterology Gastrointestinal Agents Granulocytes Health and Medicine Hematologic Diseases and Conditions Hemic and Immune Systems Hepatitis Immunology Infectious Diseases and Conditions Leukocyte Diseases and Conditions Leukocyte Disorders Liver Diseases and Conditions Pharmaceuticals Sulfasalazine Sulfasalazine Therapy Sulfonamides 1804 1804 1 10/24/23 20231023 NES 231023 2023 OCT 27 (NewsRx) -- By a News Reporter-Staff News Editor at Hepatitis Weekly -- New study results on acute hepatitis have been published. [Extracted from the article]

In order to match the degradation of drug carriers and their retention time in the colon, a rapidly degradable konjac glucomannan (KGM) hydrogel was designed for colon target drug release. Keywords: 5-aminosalicylates; Alcohols; Drugs and Therapies; Gastrointestinal Agents; Health and Medicine; Hydrogel; Olsalazine Therapy; Organic Chemicals; Pharmaceuticals; Polyethylene Glycols EN 5-aminosalicylates Alcohols Drugs and Therapies Gastrointestinal Agents Health and Medicine Hydrogel Olsalazine Therapy Organic Chemicals Pharmaceuticals Polyethylene Glycols 2558 2558 1 10/03/23 20231006 NES 231006 2023 OCT 6 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Researchers detail new data in gastrointestinal agents. [Extracted from the article]

Keywords: Ciudad de Mexico; Mexico; North and Central America; 1-Naphthylamine; 5-aminosalicylates; Antidepressants; Biogenic Amines; Catecholamines; Dopamine; Dopamine Hydrochloride; Drug Delivery; Drug Delivery Systems; Drugs and Therapies; Gastrointestinal Agents; Health and Medicine; Olsalazine Therapy; Organic Chemicals; Pharmaceuticals; Psychotherapeutic Agents; Selective Serotonin Reuptake Inhibitors; Sertraline; Sertraline Therapy EN Ciudad de Mexico Mexico North and Central America 1-Naphthylamine 5-aminosalicylates Antidepressants Biogenic Amines Catecholamines Dopamine Dopamine Hydrochloride Drug Delivery Drug Delivery Systems Drugs and Therapies Gastrointestinal Agents Health and Medicine Olsalazine Therapy Organic Chemicals Pharmaceuticals Psychotherapeutic Agents Selective Serotonin Reuptake Inhibitors Sertraline Sertraline Therapy 1267 1267 1 10/03/23 20231006 NES 231006 2023 OCT 6 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- A new study on Drugs and Therapies - Selective Serotonin Reuptake Inhibitors is now available. According to the news editors, the research concluded: "Due to similarity of systems of dopamine and sertraline with that of phenylethylamine, we conclude that Mg2(olz) is also capable to encapsulate and release these two drugs, being a good proposal as a drug delivery system.". [Extracted from the article]

5-aminosalicylates, Amides, Antiinfectives, Drugs and Therapies, Gastrointestinal Agents, Health and Medicine, Pharmaceuticals, Sulfasalazine, Sulfasalazine Therapy, Sulfonamides Keywords: 5-aminosalicylates; Amides; Antiinfectives; Drugs and Therapies; Gastrointestinal Agents; Health and Medicine; Pharmaceuticals; Sulfasalazine; Sulfasalazine Therapy; Sulfonamides EN 5-aminosalicylates Amides Antiinfectives Drugs and Therapies Gastrointestinal Agents Health and Medicine Pharmaceuticals Sulfasalazine Sulfasalazine Therapy Sulfonamides 941 941 1 09/11/23 20230915 NES 230915 2023 SEP 15 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Data detailed on antiinfectives have been presented. [Extracted from the article]

Keywords for this news article include: Department for Neurology, Forde, Norway, Europe, Antiinfectives, Antimetabolites, Antineoplastics, Antipsoriatics, Antirheumatics, Pharmaceuticals, Sulfonamides, 5-aminosalicylates, Drugs and Therapies, Health and Medicine, Leflunomide Therapy, Methotrexate Therapy, Sulfasalazine Therapy, Adverse Drug Reactions, Gastrointestinal Agents. Keywords: 5-aminosalicylates; Adverse Drug Reactions; Antiinfectives; Antimetabolites; Antineoplastics; Antipsoriatics; Antirheumatics; Drugs and Therapies; Gastrointestinal Agents; Health and Medicine; Leflunomide Therapy; Methotrexate Therapy; Pharmaceuticals; Sulfasalazine Therapy; Sulfonamides EN 5-aminosalicylates Adverse Drug Reactions Antiinfectives Antimetabolites Antineoplastics Antipsoriatics Antirheumatics Drugs and Therapies Gastrointestinal Agents Health and Medicine Leflunomide Therapy Methotrexate Therapy Pharmaceuticals Sulfasalazine Therapy Sulfonamides 393 393 1 07/24/23 20230725 NES 230725 2023 JUL 28 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- A new study on antiinfectives is now available. Adverse Drug Reactions, Antiinfectives, Antimetabolites, Antineoplastics, Antipsoriatics, Antirheumatics, Drugs and Therapies, Gastrointestinal Agents, Health and Medicine, Leflunomide Therapy, Methotrexate Therapy, Pharmaceuticals, Sulfasalazine Therapy, Sulfonamides, 5-aminosalicylates. [Extracted from the article]

Antiinfectives, Drugs and Therapies, Gastrointestinal Agents, 5-aminosalicylates, Health and Medicine, Mesalamine Therapy, Pharmaceuticals, Sulfasalazine Therapy, Sulfonamides Keywords: 5-aminosalicylates; Antiinfectives; Drugs and Therapies; Gastrointestinal Agents; Health and Medicine; Mesalamine Therapy; Pharmaceuticals; Sulfasalazine Therapy; Sulfonamides EN 5-aminosalicylates Antiinfectives Drugs and Therapies Gastrointestinal Agents Health and Medicine Mesalamine Therapy Pharmaceuticals Sulfasalazine Therapy Sulfonamides 1713 1713 1 07/10/23 20230714 NES 230714 2023 JUL 14 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Current study results on antiinfectives have been published. Mesalamine pellets were prepared by Coating drug solution on sugar sphere followed by functional coating. [Extracted from the article]

Keywords: Johannesburg; South Africa; Africa; 5-aminosalicylates; Acetic Acids; Amides; Antiinfectives; Drugs and Therapies; Emerging Technologies; Gastrointestinal Agents; Health and Medicine; Nanotechnology; Peracetic Acid; Pharmaceuticals; Physics; Quantum Dots; Quantum Physics; Sulfasalazine; Sulfasalazine Therapy; Sulfonamides EN Johannesburg South Africa Africa 5-aminosalicylates Acetic Acids Amides Antiinfectives Drugs and Therapies Emerging Technologies Gastrointestinal Agents Health and Medicine Nanotechnology Peracetic Acid Pharmaceuticals Physics Quantum Dots Quantum Physics Sulfasalazine Sulfasalazine Therapy Sulfonamides 692 692 1 06/19/23 20230623 NES 230623 2023 JUN 23 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Research findings on Nanotechnology - Quantum Dots are discussed in a new report. For more information on this research see: Advanced Oxidation Processes for Pharmaceutical Degradation and Disinfection of Wastewater: Peracetic Acid and Graphene Oxide Quantum Dots. [Extracted from the article]

Keywords: Corvallis; State:Oregon; United States; North and Central America; 5-aminosalicylates; Amides; Antiinfectives; Drug Carriers; Drug Delivery Systems; Drug Development; Drugs and Therapies; Gastrointestinal Agents; Health and Medicine; Pharmaceuticals; Sulfasalazine; Sulfasalazine Therapy; Sulfonamides EN Corvallis State:Oregon United States North and Central America 5-aminosalicylates Amides Antiinfectives Drug Carriers Drug Delivery Systems Drug Development Drugs and Therapies Gastrointestinal Agents Health and Medicine Pharmaceuticals Sulfasalazine Sulfasalazine Therapy Sulfonamides 2023 FEB 3 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- A new study on Drugs and Therapies - Antiinfectives is now available. Corvallis, State:Oregon, United States, North and Central America, 5-aminosalicylates, Amides, Antiinfectives, Drug Carriers, Drug Delivery Systems, Drug Development, Drugs and Therapies, Gastrointestinal Agents, Health and Medicine, Pharmaceuticals, Sulfasalazine Therapy, Sulfonamides, Sulfasalazine. [Extracted from the article]